Enhanced antithrombotic mechanisms in patients with maturity-onset diabetes mellitus without thromboembolic complications. 1981

G Grignani, and G Gamba, and D Geroldi, and L Pacchiarini, and B Solerte, and E Ferrari, and E Ascari

Some haemostatic parameters have been evaluated in a group of rigorously selected patients with maturity-onset diabetes mellitus without thromboembolic complications and in apparently normal subjects of the same age before and after the venous occlusion test (VOT). In basal conditions diabetics had higher levels of AT III as biological activity and higher fibrinolytic and antifibrinolytic activities than controls. After VOT, F VIII R:Ag increased significantly in both groups, more markedly in controls than in diabetics, while F VIII: C showed no modification. Also AT III R:Ag increased after the test, but such variation was significant only in diabetics; on the contrary, the biological activity of AT III was always significantly decreased after the test. After VOT there were also in both groups highly significant increases in the fibrinolytic and antifibrinolytic activities. Finally, HbA1c levels directly correlated with AT III as biological activity before VOT, but with no other parameter either before or after the test. These data suggest the existence in patients with diabetes mellitus without thromboembolic complications of an activated protective mechanism against intravascular clotting.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010960 Plasminogen Activators A heterogeneous group of proteolytic enzymes that convert PLASMINOGEN to FIBRINOLYSIN. They are concentrated in the lysosomes of most cells and in the vascular endothelium, particularly in the vessels of the microcirculation. Extrinsic Plasminogen Activators,Plasminogen Activator,Uterine-Tissue Plasminogen Activator,Uterine Tissue Plasminogen Activator
D003250 Constriction The act of constricting. Clamping,Clampings,Constrictions
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D004211 Disseminated Intravascular Coagulation A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS. Consumption Coagulopathy,Coagulation, Disseminated Intravascular,Disseminated Coagulation, Intravascular,Intravascular Coagulation, Disseminated,Intravascular Disseminated Coagulation,Coagulation, Intravascular Disseminated,Coagulations, Disseminated Intravascular,Coagulations, Intravascular Disseminated,Coagulopathies, Consumption,Coagulopathy, Consumption,Consumption Coagulopathies,Disseminated Coagulations, Intravascular,Disseminated Intravascular Coagulations,Intravascular Coagulations, Disseminated,Intravascular Disseminated Coagulations
D005169 Factor VIII Factor VIII of blood coagulation. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin. Coagulation Factor VIII,Factor VIII Clotting Antigen,Factor VIII Coagulant Antigen,Factor VIII Procoagulant Activity,Thromboplastinogen,Blood Coagulation Factor VIII,F VIII-C,Factor 8,Factor 8 C,Factor Eight,Factor VIIIC,Hyate-C,Hyatt-C,F VIII C,Hyate C,HyateC,Hyatt C,HyattC
D005260 Female Females
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses
D006441 Hemoglobin A Normal adult human hemoglobin. The globin moiety consists of two alpha and two beta chains.

Related Publications

G Grignani, and G Gamba, and D Geroldi, and L Pacchiarini, and B Solerte, and E Ferrari, and E Ascari
January 1969, Vrachebnoe delo,
G Grignani, and G Gamba, and D Geroldi, and L Pacchiarini, and B Solerte, and E Ferrari, and E Ascari
November 1976, JAMA,
G Grignani, and G Gamba, and D Geroldi, and L Pacchiarini, and B Solerte, and E Ferrari, and E Ascari
June 1976, JAMA,
G Grignani, and G Gamba, and D Geroldi, and L Pacchiarini, and B Solerte, and E Ferrari, and E Ascari
May 1971, Geriatrics,
G Grignani, and G Gamba, and D Geroldi, and L Pacchiarini, and B Solerte, and E Ferrari, and E Ascari
May 1971, Geriatrics,
G Grignani, and G Gamba, and D Geroldi, and L Pacchiarini, and B Solerte, and E Ferrari, and E Ascari
January 1976, Proceedings of the Australian Association of Neurologists,
G Grignani, and G Gamba, and D Geroldi, and L Pacchiarini, and B Solerte, and E Ferrari, and E Ascari
March 2012, Pediatric diabetes,
G Grignani, and G Gamba, and D Geroldi, and L Pacchiarini, and B Solerte, and E Ferrari, and E Ascari
January 1973, Journal of the National Medical Association,
G Grignani, and G Gamba, and D Geroldi, and L Pacchiarini, and B Solerte, and E Ferrari, and E Ascari
March 1981, Journal of the Indian Medical Association,
G Grignani, and G Gamba, and D Geroldi, and L Pacchiarini, and B Solerte, and E Ferrari, and E Ascari
January 1979, Current medical research and opinion,
Copied contents to your clipboard!